Glucagon like peptide 1 as a diagnostic biomarker of acute mesenteric ischemia – GLUBAMI

Acute mesenteric ischemia or intestinal infarction is an absolute medical emergency, as can be myocardial infarction. However, if there are ways to diagnose myocardial infarction (electrocardiograms, blood biomarkers), there is currently no way to diagnose digestive infarction early. This lack of early diagnosis is responsible for a mortality rate of 60 to 80% of patients who are victims of bowel infarction. In the rare cases where the patient survives, he then presents heavy intestinal sequelae. It is interesting to note that the highly unfavorable prognosis of this pathology is directly linked to this delay in diagnosis. It is therefore essential to be able to recognize early mesenteric ischemia in order not to see it evolve into late mesenteric ischemia associated with the death of the patient. To date, there is no biomarker allowing physicians and surgeons an early diagnosis allowing rapid management of patients with mesenteric ischemia. We have recently identified and provided the proof of concept that Glucagon Like Peptide 1 (GLP-1), a hormone secreted by the intestine, could be this much sought-after biomarker which would allow an early diagnosis of intestinal infarction.This project consists in validating the biological relevance of this biomarker in the clinic with patients who have been hospitalized and diagnosed for mesenteric ischemia. Finally, this project also aims to understand the role of GLP-1 during its early secretion when the barrier function of the intestine is disturbed by combining complementary approaches ranging from in vitro to in vivo via the ex-vivo.